Neuromuscular

Divya Jayaraman, MD, PhD, a pediatric neuromuscular specialist at Columbia University Irving Medical Center, discussed how multidisciplinary care teams in spinal muscular atrophy are adapting to a growing number of treatment options.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 7, 2026.

Six FDA PDUFA decisions this fall could reshape care in Alzheimer disease, DMD, Sanfilippo syndrome, Alexander disease, and SMA, here's what clinicians need to know about the data behind each.

In recognition of SMA Awareness Month, held annually throughout August, NeurologyLive® summarized the latest literature on the multidisciplinary care approach for patients living with spinal muscular atrophy.

Elizabeth Ferluga, MD, and Kristen Fortino discuss a newly launched virtual care program, the barriers facing patients with ataxia, and the potential for remote access to specialized care to improve diagnosis, treatment, and clinical trial connectivity.

The associate professor at the University of Michigan covered the 2026 Peripheral Nerve Society Annual Meeting, highlighting emerging themes in GBS, SMA, TTR neuropathy, RFC1, and what is still keeping the field up at night.

The FDA has accepted Saol Therapeutics' resubmitted NDA for SL1009 in pyruvate dehydrogenase complex deficiency, setting a new PDUFA target action date of December 30, 2026.

Catch up on any of the neurology headlines you may have missed in July 2026, compiled into 1 place by the NeurologyLive® team.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 31, 2026.

The nonbinding vote casts doubt on the therapy's path to approval ahead of an August 22 FDA decision, capping over a year of regulatory back-and-forth over the strength of its phase 3 data.

Stephanie Fradette, PharmD, SVP, Head of Rare Neurology Development Unit at Biogen, gave commentary on the FDA designation and long-term outlook for salanersen, an investigational antisense agent for spinal muscular atrophy.

Postmortem analyses of 8 individuals with SOD1-ALS who received tofersen showed widespread drug distribution across somatic motor system tissues and reductions of up to 84% in lumbar spinal cord SOD1 protein levels.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 24, 2026.

Andrew Lee, MD, PhD, cofounder and CEO of Spot Biosystems, discusses the company's extracellular vesicle platform, the first non-viral delivery of full-length dystrophin in patients with Duchenne muscular dystrophy.

Epilepsy expert Susan Duberstein, MD, explores how multidisciplinary neurocutaneous clinics improve diagnosis, surveillance, care coordination, and long-term outcomes for patients with complex neurocutaneous syndromes.

Spinogenix’s codabakalner, an investigational BK channel modulator, is currently being evaluated in CLARITY, a phase 2b/3 trial for the treatment of patients with Fragile X syndrome.

Ahead of World Brain Day, NeurologyLive explores 5 emerging strategies for preventing neurologic disease, from modifiable dementia risk factors to GLP-1 drugs, sleep science, the gut brain axis, and wearable technology.

A look at where things stand for Fragile X syndrome drug development, covering seven agents across four mechanisms as the field regroups from two recent Phase 3 setbacks.

Brett Morrison, MD, PhD, associate professor at Johns Hopkins University, recaps his PNS 2026 presentation on current and emerging biomarkers in peripheral nerve disease, from neurofilament light chain to muscle MRI and microRNA.

The FDA granted priority review to zeleciment rostudirsen for exon 51-amenable Duchenne muscular dystrophy, with a PDUFA target action date of January 21, 2027.

Here's some of what is coming soon to NeurologyLive® this week.

Here's some of what is coming soon to NeurologyLive® this week.